-
Maria Carmen Mulero, PhD
Maria Mulero Roig, PhD (Project Scientist III) is an expert protein chemist with extensive experience in the purification and analysis of difficult proteins and investigation of their roles in normal and malignant cells.
-
Dennis Gately, PhD
Dennis Gately, PhD (Visiting Scientist) has had a career in the field of antibody-drug conjugates and is an expert in the design, production, and testing of novel protein therapeutics.
-
Clara Wong, MS
Clara Wong, BS (Staff Research Associate I) is a cell and molecular biologist with experience in experimental therapeutics including both in vitro and in vivo techniques for assessment of purity, cytotoxicity and in efficacy.
-
Sukshala Jadhav, PhD
Sukshala Jadhav, Ph.D. is a cell biologist trained in experimental therapeutics including the testing of drugs against human tumor cell lines, use of HPLC and ELISA assays for the measurement of drug concentrations in plasma and other biologic fluids, and the conduct of in vivo studies of the efficacy and safety of novel cancer drugs in xenograft models.
-
Nikaash Bahl
Nikaash Bahl is an undergraduate student taking independent study courses in the Howell Laboratory. His work is focused on the use of flow cytometric and other techniques to measure the binding and cellular uptake of novel protein therapeutics.
About the Team
Stephen B. Howell, MD
Stephen B. Howell, MD is a medical oncologist and Distinguished Professor of Medicine at the University of California, San Diego. He is a graduate of Harvard Medical School and was trained as a medical oncologist and pharmacologist at the Massachusetts General Hospital, the National Institutes of Health and the Dana Farber Cancer Institute. Dr. Howell is head of Laboratory of Pharmacology at the Moores Cancer Center. He is past director of the Cancer Therapeutics Training Program and the co-head of the Solid Tumor Therapeutics Program of the Cancer Center. His work focuses on the development of novel drugs and drug delivery systems for the treatment of cancer. He is the author of more than 370 peer-reviewed research articles. Dr. Howell conducted much of the early pharmacokinetic studies and clinical trials work on intraperitoneal chemotherapy for the treatment of ovarian cancer. His laboratory has contributed importantly to the current understanding of how the platinum-containing drugs enter, traffic through and exit from ovarian cancer cells, and how such cells become resistant to these drugs.